Given both the marked ITH known to occur in ccRCC [8] and the moderately frequent SETD2‐mutation‐independent loss of H3K36me3 and SETD2 downregulation [3, 37], we curated a ‘high confidence’ set of primary ccRCC with intact SETD2 (no SETD2 mutation with high expression) to compare with SETD2‐deficient ccRCC (biallelic SETD2 inactivation accompanied by reduced expression; 12 ccRCCs from each group (Table S3)). Here, SETD2 is linked to nonpapillary renal cell carcinoma.